Idioma:

Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results

Russ, G. R. ; Tedesco‐Silva, H. ; Kuypers, D. R. ; Cohney, S. ; Langer, R. M. ; Witzke, O. ; Eris, J. ; Sommerer, C. ; von Zur‐Mühlen, B. ; Woodle, E. S. ; Gill, J. ; Ng, J. ; Klupp, J. ; Chodoff, L. ; Budde, K.

American journal of transplantation, 2013-07, Vol.13 (7), p.1746-1756 [Periódico revisado por pares]

Hoboken, NJ: Wiley

Texto completo disponível

Citações Citado por

Enviar para

Título:
Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results
Autor: Russ, G. R. ; Tedesco‐Silva, H. ; Kuypers, D. R. ; Cohney, S. ; Langer, R. M. ; Witzke, O. ; Eris, J. ; Sommerer, C. ; von Zur‐Mühlen, B. ; Woodle, E. S. ; Gill, J. ; Ng, J. ; Klupp, J. ; Chodoff, L. ; Budde, K.
Assuntos: Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Biopsy ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Efficacy ; enteric‐coated mycophenolic acid ; Follow-Up Studies ; Glomerular Filtration Rate - drug effects ; Glomerular Filtration Rate - physiology ; Graft Rejection - drug therapy ; Graft Rejection - immunology ; Graft Rejection - pathology ; Immunosuppressive Agents - administration & dosage ; Kidney - pathology ; Kidney - physiopathology ; Kidney Transplantation ; Kinases ; Medical sciences ; Pharmacology. Drug treatments ; Pyrroles - administration & dosage ; Quinazolines - administration & dosage ; Retrospective Studies ; sotrastaurin ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; tacrolimus ; Tacrolimus - administration & dosage ; Transplants & implants ; Treatment Outcome
É parte de: American journal of transplantation, 2013-07, Vol.13 (7), p.1746-1756
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
Descrição: Sotrastaurin, a novel immunosuppressant, blocks early T cell activation through protein kinase C inhibition. Efficacy and safety of sotrastaurin with tacrolimus were assessed in a dose‐ranging non‐inferiority study in renal transplant recipients. A total of 298 patients were randomized 1:1:1:1 to receive sotrastaurin 100 (n = 77; discontinued in December 2011) or 200 mg (n = 73) b.i.d. plus standard tacrolimus (sTAC; 5–12 ng/mL), sotrastaurin 300 mg (n = 75) b.i.d. plus reduced tacrolimus (rTAC; 2–5 ng/mL) or enteric‐coated mycophenolic acid (MPA) plus sTAC (n = 73); all patients received basiliximab and corticosteroids. Composite efficacy failure (treated biopsy‐proven acute rejection ≥ grade IA, graft loss, death or loss to follow up) rates at Month 12 were 18.8%, 12.4%, 10.9% and 14.0% for the sotrastaurin 100, 200 and 300 mg, and MPA groups, respectively. The median estimated glomerular filtration rates were 55.7, 53.3, 64.9 and 59.2 mL/min, respectively. Mean heart rates were faster with higher sotrastaurin doses and discontinuations due to adverse events and gastrointestinal adverse events were more common. Fewer patients in the sotrastaurin groups experienced leukopenia than in the MPA group (1.3–5.5% vs. 16.5%). Sotrastaurin 200 and 300 mg had comparable efficacy to MPA in prevention of rejection with no significant difference in renal function between the groups. This phase II study demonstrates that sotrastaurin, a novel selective protein‐kinase‐C inhibitor, shows higher effi cacy failure and higher treatment discontinuation rates, but some improvement in renal allograft function compared to cyclosporine in de novo kidney transplant recipients receiving basiliximab induction, everolimus, and prednisone.
Editor: Hoboken, NJ: Wiley
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 12 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results

Russ, G. R. ; Tedesco‐Silva, H. ; Kuypers, D. R. ; Cohney, S. ; Langer, R. M. ; Witzke, O. ; Eris, J. ; Sommerer, C. ; von Zur‐Mühlen, B. ; Woodle, E. S. ; Gill, J. ; Ng, J. ; Klupp, J. ; Chodoff, L. ; Budde, K.

Hoboken, NJ: Wiley

Buscando em bases de dados remotas. Favor aguardar.